Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.78−1.50 (-6.44%)
Close on Nov 11, 2026Market cap $2.06BP/E –Yield –
Replimune cash
Cash and short-term investments held at the end of each period.
Replimune's cash was $307.83M at Sep 30, 2026. For fiscal 2026 it was $268.89M, down 44.6% from the year before. Over ten years it grew 34.0% a year on average. The highest annual figure on record is $585.02M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $268.89M | -44.6% |
| FY2025 | Mar 31, 2025 | $485.51M | +14.9% |
| FY2024 | Mar 31, 2024 | $422.37M | -27.8% |
| FY2023 | Mar 31, 2023 | $585.02M | +47.3% |
| FY2022 | Mar 31, 2022 | $397.29M | -16.9% |
| FY2021 | Mar 31, 2021 | $477.94M | +180.8% |
| FY2020 | Mar 31, 2020 | $170.19M | +25.1% |
| FY2019 | Mar 31, 2019 | $136.00M | +120.7% |
| FY2018 | Mar 31, 2018 | $61.63M | +198.1% |
| FY2017 | Mar 31, 2017 | $20.67M | +43.5% |
| FY2016 | Mar 31, 2016 | $14.41M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | $307.83M | -5.4% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $195.33M | -51.8% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $268.89M | -44.6% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $269.14M | -50.0% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $325.35M | -25.0% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $405.05M | -14.0% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $485.51M | +14.9% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $538.24M | +15.0% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $433.76M | -13.0% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $470.82M | -12.9% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $422.37M | -27.8% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $467.99M | -24.3% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $498.40M | +33.5% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $540.74M | +36.3% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $585.02M | +47.3% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $618.01M | +46.5% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $373.46M | -14.6% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $396.72M | -13.8% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $397.29M | -16.9% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $421.81M | -14.8% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $437.41M | +77.6% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $459.97M | +74.6% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $477.94M | +180.8% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $494.91M | +173.6% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $246.28M | +103.2% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $263.40M | +115.1% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $170.19M | +25.1% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $180.88M | +26.5% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $121.22M | -18.7% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $122.44M | +127.2% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $136.00M | +120.7% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $142.99M | +264.7% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $149.08M | +120.2% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $53.89M | +235.9% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $61.63M | +198.1% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $39.20M | +172.1% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $67.69M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $16.04M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $20.67M | – |
| Q4 FY2016CQ1 2016 | Mar 31, 2016 | $14.41M | – |
See a number that looks wrong?